Abram Scientific, Inc.

Abram Scientific, based in the US, founded in 2011 by CEO Abhishek Ramkumar specializes in precision blood management solutions, enhancing clinical outcomes through advanced diagnostic tools for coagulation diagnostics. Abram Scientific operates in the field of blood management solutions, focusing on coagulation diagnostics. The company is headquartered in Menlo Park, US. Recently, it raised USD 11.

75 mn in a Series A funding round, led by Octapharma Limited, marking an important step in its growth. The total amount raised by the company amounts to USD 11. 75 mn. Abram Scientific specializes in precision blood management solutions aimed at enhancing clinical outcomes in coagulation diagnostics.

The company’s primary offerings include advanced diagnostic tools that facilitate accurate and timely assessment of blood coagulation parameters. These products are designed to improve patient management in various healthcare settings, particularly in surgical and critical care environments where effective blood management is crucial. Abram Scientific targets hospitals, clinics, and specialized healthcare providers as its customer base, ensuring that healthcare professionals can deliver optimal care to patients requiring coagulation monitoring. The company's products are marketed primarily in North America and Europe, where there is a growing need for innovative medical diagnostics and blood management solutions.

Abram Scientific generates revenue through direct sales of its coagulation diagnostic products to healthcare institutions and professionals. The company employs a business-to-business model, establishing partnerships with hospitals and medical facilities to supply its diagnostic tools. Transactions typically involve structured agreements whereby healthcare providers purchase devices and consumables as needed to support their patient care initiatives. Although specific pricing details are proprietary, the revenue model includes bulk purchase agreements and possibly subscription services for ongoing supply and support.

The company's flagship products are integral to the blood management protocols of its clients, reinforcing the importance of precision diagnostics in improving patient outcomes. Looking ahead, Abram Scientific plans to expand its product line with new diagnostic tools aimed at enhancing blood management protocols. The company is also considering expansion into new geographic markets beyond North America and Europe, although targeted regions have yet to be disclosed. The recent funding of USD 11.

75 mn will support these initiatives, ensuring that Abram Scientific can continue to develop and provide advanced solutions for coagulation diagnostics.